RxDoctor Payments Data

Sabry Omar, MD

Interventional Cardiology · Venice, FLNPI 1689939910

Payments from drug & device makers

$14,885in general payments, 2019–2025

Across 366 payments — averaging $40.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Penumbra, Inc.$2K
  • Boston Scientific$2K
  • Edwards Lifesciences$1K
  • Biotronik Inc.$1K
  • Shockwave Medical, Inc$763
  • plus $6K from 36 others

What the payments were for

  • Travel & lodging$3,32222%
  • Food & beverage$11,51977%
  • Education$440%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,885 in reported general payments places this provider in the 60th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$2,294,880
Medicare patients
1,763
Services billed
14,875

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban466$593,481
EntrestoSacubitril/Valsartan133$211,444
XareltoRivaroxaban70$73,670
BrilintaTicagrelor60$60,483
Repatha SureclickEvolocumab52$47,746
OzempicSemaglutide15$18,083
Prasugrel Hcl105$12,354
Praluent PenAlirocumab21$12,286
Metoprolol Succinate839$9,444
Atorvastatin Calcium733$6,572
ClopidogrelClopidogrel Bisulfate556$6,314
Rosuvastatin Calcium298$3,965
Amiodarone Hcl134$3,400
Losartan Potassium392$2,932
Midodrine Hcl16$2,846

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$516$593,481466 claims
NovartisEntresto$576$211,444133 claims
Johnson & JohnsonXarelto$152$73,67070 claims
AstraZenecaBrilinta$112$60,48360 claims
Novo NordiskOzempic$147$18,08315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Venice

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →